Pancreatic Cancer Clinical Trials

• Histologically and/or cytologically proven locally advanced pancreatic adenocarcinoma

• Target lesion is technically amenable for Alpha DaRT sources implantation.

• Measurable lesion per RECIST (version 1.1) criteria

• Stable disease or tumor response per RECIST (version 1.1) criteria compared to before initiation of mFOLFIRINOX

• Lesion size ≤ 5 cm in the longest diameter

• Interstitial radiation indication validated by a multidisciplinary team which includes an oncologist, a radiation oncologist, radiologist, gastroenterologist and a surgeon specialized in pancreatic oncology in the case that a surgical emergency occurs during the procedure

• Patients have received 8 - 12 cycles of mFOLFIRINOX

• ECOG Performance Status Scale 0 - 1

• Life expectancy is more than 6 months

• WBC ≥ 3500/µl, granulocyte ≥ 1500/µl

• Platelet count ≥60,000/µl

• Creatinine ≤1.9 mg/dL

• AST and ALT ≤ 2.5 X upper limit of normal (ULN)

• INR \< 1.4 for patients not on Warfarin

• Age ≥18 years old

• Subjects are willing and able to sign an informed consent form

• Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test before the Ra-224 implantation and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after initiation of Alpha DaRT therapy

• Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after DaRT insertion.